The present study was aimed to evaluate the human Growth Hormone (hGH) stimulatory potential of GenF20 Plus
in aging adults. This was a double blind, randomized, crossover, placebo-controlled study and a total of 30 otherwise
healthy participants were stratified to either receive GenF20 Plus or placebo in a cross-over manner. On day 3 and
11 of assessment, blood samples were collected before and after study product administration, and hGH levels were
assessed using electro-chemiluminescence immunoassay. Treatment exposure across time was determined using area
under concentration-time curve, whereas fatigue severity was evaluated by a visual analogue scale. Results indicated
that GenF20 Plus levels peaked at 30 minutes and further at 90 minutes, and hGH levels in GenF20 Plus arm were
significantly higher than placebo; p<0.05. Furthermore, a higher mean area under curve was observed for GenF20
Plus arm (18.78) as compared to the placebo (10.38) group at the end of study period; p=0.056. The VAS score
though reduced in GenF20 group of participants was not significant; p=0.06.
